Chronic obstructive pulmonary disease (COPD) is a worldwide prevalent disease. During recent years, increasing attention has been directed to the importance of the contribution of small airways in respiratory diseases. The small airways (usually defined as those with an internal diameter of \<2 mm) are recognized as the major site of resistance to airflow in obstructive lung disease. Although small airway disease is known in chronic airway diseases, the importance of small airway dysfunction on disease control, exacerbations and quality of life, and the importance of taking place among treatable targets is not clear. Therefore, our aim in the study is to determine the frequency of small airway dysfunction in COPD. Our secondary aim is to evaluate the role of small airway dysfunction in disease severity, disease phenotypes, disease control, quality of life and its effect on predicting the risk of exacerbation and its role among treatable targets in chronic airway diseases.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Small airway dysfunction will be evaluated by performing impulse oscillometry test.
Timeframe: through study completion, an average of 1 year
Small airway dysfunction will be evaluated by thorax computed tomography.
Timeframe: through study completion, an average of 1 year
Small airway dysfunction will be evaluated by body plethysmography test.
Timeframe: through study completion, an average of 1 year
Symptoms will be evaluated by Modified Medical Research Council Dyspnea Scale (mMRC).
Timeframe: through study completion, an average of 1 year
The number of moderate and severe exacerbations over a 1 year period will be recorded.
Timeframe: through study completion, an average of 1 year
Forced expiratory volume in 1 second (fev1) change will be evaluated by spirometric pulmonary function test.
Timeframe: through study completion, an average of 1 year